Community-Acquired Pneumonia Treatment Guidelines

First-Line Treatment Recommendations

The American College of Physicians and other guideline societies recommend amoxicillin 3 g/day as the reference standard treatment for community-acquired pneumonia in adults without risk factors, particularly for suspected pneumococcal pneumonia 1, 2
For patients under 40 years with suspected atypical pathogens, macrolides are preferred as first-line therapy 1
Combined therapy with amoxicillin plus a macrolide is recommended for hospitalized patients with non-severe pneumonia 1
A broad-spectrum β-lactamase stable antibiotic plus a macrolide is the standard approach for severe pneumonia requiring hospitalization 1

The French and IDSA guidelines explicitly state that trimethoprim-sulfamethoxazole is not recommended for community-acquired pneumonia due to inadequate activity against penicillin-resistant S. pneumoniae 1
Clinical guidelines consistently prioritize amoxicillin, macrolides, or respiratory fluoroquinolones over TMP-SMX 1
Only 78.1% of H. influenzae isolates show susceptibility to TMP-SMX, with even lower activity expected against K. pneumoniae 3
Increasing bacterial resistance has compromised co-trimoxazole's utility, relegating it to second-line status even for less serious infections 3

For Listeria monocytogenes encephalitis in penicillin-allergic patients, TMP-SMX is an alternative 4
For carbapenemase-producing K. pneumoniae with documented TMP-SMX susceptibility, it may be used, though newer agents are preferred for serious infections 3

Uncomplicated pneumonia requires 7 days of appropriate antibiotic therapy 1
Severe microbiologically undefined pneumonia requires 10 days of treatment 1
Specific pathogens, such as Legionella, Staphylococcus, and gram-negative enteric bacilli, require 14-21 days of treatment 1
Short-course treatment (≤6 days) for community-acquired pneumonia has been shown to be as effective as longer treatment with fewer serious adverse events and lower mortality 5

Never use TMP-SMX as empiric therapy for serious pneumonia without susceptibility data, as resistance rates are too high to ensure adequate coverage 3
TMP-SMX is specifically NOT recommended for pediatric pneumonia caused by K. pneumoniae or other serious respiratory infections 3
Avoid treating all respiratory infections with antibiotics when viral etiology is likely 2
Do not use antibiotics with poor activity against S. pneumoniae for respiratory infections 2

If a patient fails to improve on initial therapy within 48-72 hours, treatment should be reassessed 1, 2
Clinical stability should guide decisions about treatment duration 5, 1
Treatment should not be changed within the first 72 hours unless the patient's clinical condition worsens 2